ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Rhoads Suggests Plan For 200 Clinical Centers

January 28, 1977

NCI-Approved Clinical Trials Listed For May 2001

June 29, 2001

Rescission Cuts $5-6 Mil. From NCI FY94 Appropriations , Affects Intramural Program

March 11, 1994

Finasteride Cut Risk Of Prostate Cancer In Large Trial, But Value In Clinic Unclear.

June 27, 2003

In Brief: Lombardi Comprehensive Designation Renewed; Yale Plans Breast Cancer Lab

September 26, 1997

713 Nurses Pass Certification exam At ONS Congress

July 8, 1988